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For and against
Social insurance—the right way forward for health care in
the United Kingdom?
The NHS in the United Kingdom is struggling to meet the needs of patients as costs continue to
rise. Does the current system of funding need to change? David G Green and Benedict Irvine argue
for a system based on social insurance, while Martin McKee and colleagues suggest that a tax based
system is more equitable
FOR Comparing systems of funding health›care is controversial. We suggest, however,
that the following six questions should help to put the
controversy on an evidence based footing. We believe
that the case for social insurance deserves a more seri›
ous hearing than the British government has so far
given it.
Value for money—Can individuals tell whether they
are getting good value for money? It is impossible for
taxpayers to make a well informed judgment about
value for money because they have no knowledge of
the amount being paid nor any ability to vary it. Social
insurance schemes allow individuals to see clearly
(usually on pay slips) how much they are paying
towards care. In Germany employers and employees
make equal payments (totalling on average about 13%
of the salary) to the independent sickness fund chosen
by each individual. In France sickness funds are usually
run by a board comprising employers and trade
unions, and individuals cannot choose which sickness
fund to use. In the past, employers in France paid
about two thirds of the premium, but recently the share
paid by individuals has been increased. In Switzerland
there are competing insurers, and premiums are paid
solely by individuals.
Standard of care—Do poor people enjoy a high
standard of care? The standard of care is generally
lower for people of all incomes in the United Kingdom
than other European countries of similar wealth. In
1993 Wagstaff and van Doorslaer tentatively noted that
higher healthcare spending in Europe seemed to “buy”
some reduction in health inequality.1 They also
concluded that countries that spend more per capita
on health may have lower levels of income related
inequality in morbidity. France and Germany have
never claimed that their systems are egalitarian, in the
sense of aiming to provide a uniform standard across
each country. Their objective has been “solidarity”
rather than equality: they aimed to ensure that
everyone would receive the high standard of care that
middle income people chose for themselves while
accepting that more affluent individuals should be free
to pay for extras. In practice, pursuit of formal equality
in the United Kingdom has meant that the poorest
people ended up receiving a lower standard than was
normal in mainland Europe.
Patients as customers—Does the funding system put
the consumer in a weak or strong position? When
people in Britain pay the Treasury, the provider has
our money “up front” and we must put up with
whatever service we get. Under social insurance, the
payment goes to a third party, which will pay any pro›
vider chosen by the consumer. Normand and Busse
note that social insurance systems treat patients as val›
ued customers.2 This may go some way to explaining
why satisfaction rates are generally higher in countries
that have a social insurance scheme.3
Incentives—What incentives are there for providers
to offer a high standard of care? Treasury restrictions
on expenditure have an impact on UK health
outcomes.4 In Germany and France, care standards are
high, but their systems are criticised for failing to
encourage good value for money. The funds were
founded at a time when the priority for policy makers
was access. Insurers pay agreed costs incurred by “any
willing provider,” but the disadvantage of such
unfettered choice is that insurers cannot weed out pro›
viders whose standards are too low. To overcome this
problem, France and Germany have taken different
routes. France is intent on central regulation, whereas
Germany has relied on increasing competition
between sickness funds.
Effect on professional duty—Does the system have an
impact on the professional duty of clinicians to act in the
best interest of patients? Owing to political interference,
clinicians in the United Kingdom often cannot act in the
best interests of patients. Doctors have increasingly
made their dissatisfaction public. Professional autonomy
is more fully respected under a social insurance scheme,
although a brief period of controversy followed efforts
by the German government to restrict access to drugs in
the 1990s. Mossialos and Le Grand compare priority
setting decision making in the European Union and
note that in Germany and the Netherlands (which also
has a social insurance system) there are several
French patients pay into a sickness fund
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stakeholders who can veto decisions and who are not
beholden to the government.5
Balancing expectations and resources—Has the system
proved able over time to bring the expectations of
individuals into balance with the capacity of providers
to treat patients? The UK Treasury has interests of its
own that do not necessarily coincide with those of con›
sumers. Funding health care from general taxes has
proved to be an ineffective way of bringing the expec›
tations of patients into balance with the treatment
capacity of the system. The Wanless report put the
accumulated underinvestment at £267bn ($417bn;
&425bn).6 Separation of healthcare finance from other
government expenditure allows spending levels to rise
according to demand; social insurance systems tend to
lead to higher spending than tax based systems.7 In
2000, the World Health Organization ranked countries
according to the responsiveness of their health systems
to needs: Switzerland, Luxembourg, Germany, and the
Netherlands (all with social insurance systems) ranked
second, third, fifth, and ninth in the world. Of the tax
based systems in western Europe, only Denmark (with
its highly decentralised system funded by local
taxation) achieves a similar ranking—fourth. The
United Kingdom languished in twenty sixth
position.8—David G Green, Benedict Irvine
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AGAINST
After years of debate about containing
spending on health care in the United
Kingdom a consensus has emerged that it should be
increasing. Unfortunately, this breaks down when the
debate is about how the extra funds should be raised.
The Treasury argues for continued funding from taxes
and national insurance contributions.1 Others argue
for a shift to social health insurance, accompanied by
higher spending by individuals through user charges
and private insurance, on the grounds that funding
from taxation is unsustainable.2 We believe that the
arguments for change are flawed.
Supporters of change contend that Britain is out of
step with the rest of the world. Yet other countries in
Europe rely largely on taxation. The organisation of
social insurance systems also differ considerably from
each other.3 Every system is, in some way, unique. And
no western European country has changed from a tax
based funding system to an insurance based system,
although several—including France, Italy, and Spain—
have moved or are moving in the opposite direction.4
Impact on the economy
Some commentators argue that social insurance
systems spend more on health care, but some tax based
systems, such as Sweden’s, seem able to spend at least
as much as social insurance systems. However, how the
resources are spent and the output and outcomes
achieved is surely more important. Denmark, a tax
funded system, does not spend as much as France or
Germany, but neither does it face the problems (such
as long waiting lists and staff shortages) seen in Britain.
Others have argued that the impact of the
necessary additional spending on income tax would
be politically unacceptable. Yet income tax now
accounts for only £118bn ($184bn; &188bn) of a total
tax revenue of £407bn,5 so the consequences for
income tax need not be excessive. Retaining the ability
to raise taxes from various sources, including
investment income and company profits, makes it
possible to compensate for imbalances across the
economic cycle.
In contrast, social insurance seems less sustainable.
It is more vulnerable to economic cycles and is levied
on earned income, which is growing more slowly than
investment income. Of course, shifting to earned
income would benefit those who have reduced their tax
bill by taking most of their income as dividends.
Furthermore, the cost it imposes on employment is
greater. Many firms in France and Germany already
find the cost of employment extremely burdensome.
Given industry’s reaction to a small increase in national
insurance contributions in Britain, raising the entire
health budget this way would presumably cause an
immediate exodus of firms to countries where labour
costs are lower.
Private sources of funding
Some people suggest that patients should pay more. In
France and the Netherlands about 20% of total health
German care standards are high, but are they good value?
AC
TI
O
N
PR
ES
S/
RE
X
Education and debate
London School of
Hygiene and
Tropical Medicine,
London
WC1E 7HT
Martin McKee
professor of European
public health
London School of
Economics and
Political Science,
London
WC2A 2AE
Anna Dixon
lecturer in European
health policy
LSE Health and
Social Care,
London School of
Economics and
Political Science
Elias Mossialos
codirector
489BMJ VOLUME 325 31 AUGUST 2002 bmj.com
expenditure is from private sources (patient charges
and private health insurance). Charging patients is
simply a tax on service users, who are more likely to be
poor or unemployed. No evidence exists that charges
deter only unnecessary use, and evidence from Sweden
shows that they reduce access.6
Expansion of private medical insurance is a
possibility, but the decline in individual contracts over
the past five years—with stability the result of increasing
group insurance7—suggests little popular enthusiasm.
Tax incentives would subsidise the better off, who are
most likely to purchase private insurance. As with
patient charges, this effectively transfers resources from
the poor to the rich.
Choice needs capacity
Some commentators argue that patients should have
more choice. One way is to opt completely out of the
public system. Few countries permit this as it
undermines the sharing of risk and funds between rich
and poor and between healthy and sick. In Germany,
employees earning over £25 000 can opt out of
statutory health insurance but fewer than one in four
do, mainly because of the high costs of covering
dependants.8
Choice can also be between insurers, as in Belgium,
Germany, and the Netherlands. The imbalance in risk
profile that results requires complex systems of adjust›
ment that are costly to administer.3 These are often
inadequate—for example, in the Netherlands both
public and private insurers spend more per capita on
selection than on efficiency gains (&10 v &3 by public
funds and &28 v &2 by private funds).9
Choice of provider is also possible. This is not
related to the funding mechanism and already exists in
Britain, although it is currently limited by lack of
capacity. Ironically, it may be heavily constrained by
competing insurers seeking to contain costs, as in the
United States.
It is wrong to think that social insurance eliminates
waiting lists. Like Britain, the Netherlands has long
waiting lists and sends patients abroad for elective sur›
gery.10 This is mainly an issue of investment in capac›
ity. Britain also lags behind western Europe in
investment in education, transport infrastructure, and
housing, suggesting a problem that goes beyond the
system of funding.11
New challenges
A social insurance model in Britain has some distinct
drawbacks. Given the emphasis placed on waiting lists,
it is easy to forget that health care involves more than
elective surgery. A combination of ageing populations
and new treatments increases the number of patients
with complex chronic diseases requiring coordinated
input from different health professionals. Moreover,
technological advances, especially in genetics, will
make it possible to screen for an increasing number of
disorders. Social insurance systems struggle to respond
to both challenges.
It is, however, important not to lose sight of the
most important issue, the distribution of costs and
benefits of health care in the population. The main
advantage of funding from general taxation is that it
recognises that those whose needs are greatest are least
able to pay for care. The young and the rich subsidise
the old and the poor. A shift to competing insurance
funds, no matter how well regulated, and an increase in
what people themselves pay, will inevitably relieve the
rich of this burden. Is this the real issue?—Martin
McKee, Anna Dixon, Elias Mossialos
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The importance of hospital identity
Picture the scene: 12 30 pm on Monday. I had been on call for
the weekend and had just spent the past 52 hours within the
confines of the hospital. I was still wearing blue theatre scrubs
(despite local policy prohibiting me from doing so out of
theatres), my white coat, and a stethoscope draped around my
neck and was armed with three bleeps (one of which was the
arrest bleep) and loaded with pens and scraps of paper,
tourniquets, packets of water based lubricant, rubber gloves, and
whatever else had found its way into my pockets.
I had managed to have a shave the night before, but still felt
pretty ropey, so I decided to get something to eat. My canteen tray
was loaded with a chicken wrap with some exotic leaf vegetable
I’d never heard of, a bag of salt›and›vinegar crisps, and caffeine
enriched soft drink. The customer in front of me paid and walked
off. The lady behind the till looked me up and down and, unable
to see my identification badge, asked: “Staff or visitor dear?”
James S Dawson house officer, Peterborough
We welcome articles of up to 600 words on topics such as
A memorable patient, A paper that changed my practice,My most
unfortunate mistake, or any other piece conveying instruction,
pathos, or humour. If possible the article should be supplied on a
disk. Permission is needed from the patient or a relative if an
identifiable patient is referred to. We also welcome contributions
for “Endpieces,” consisting of quotations of up to 80 words (but
most are considerably shorter) from any source, ancient or
modern, which have appealed to the reader.
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